{
    "title": "Flavopereirine vs AIDS",
    "inventor_name": "Mirko Beljanski",
    "publication_year": null,
    "device_name": "Flavopereirine pharmaceutical composition",
    "goal": "Treat human immunodeficiency virus (HIV) infection and AIDS",
    "problem_addressed": "HIV infection and progression to AIDS",
    "concept_summary": "Flavopereirine, a beta-carboline alkaloid extracted from the Pao Pereira tree, is claimed to act as a selective antiviral agent against HIV-1 when administered alone, either in vitro or in vivo, at doses of roughly 250-500 mg per administration.",
    "detailed_description": null,
    "category": "Medical & Dental Technologies",
    "principles": [
        "Selective inhibition of viral replication",
        "Beta-carboline alkaloid pharmacology",
        "Modulation of cytokine (IL-6) production"
    ],
    "scientific_domains": [
        "Molecular Biology",
        "Pharmacology",
        "Virology"
    ],
    "mechanisms_of_action": [
        "Inhibits HIV-1 replication in infected cells",
        "Reduces interleukin-6 production by monocytes"
    ],
    "materials": [
        "Flavopereirine (beta-carboline alkaloid)",
        "Pharmaceutically acceptable salts or derivatives of flavopereirine",
        "Pharmaceutically acceptable carrier"
    ],
    "energy_sources": [],
    "inputs": [
        "Flavopereirine (or salt/derivative)",
        "Carrier material"
    ],
    "outputs": [
        "Antiviral effect against HIV-1",
        "Reduced viral load",
        "Modulated immune response"
    ],
    "claimed_performance": "Effective antiviral amount of 250-500 mg per dose; selective inhibition of HIV-1 infection demonstrated in vitro and in vivo; reduction of interleukin-6 production in monocytes.",
    "experimental_evidence": "Figures 1-4 in the patent show (1) decreased cell counts after infection when flavopereirine is added, (2) lower infectious unit titres at 30-50 ug/ml, (3) decreased IL-6 production by healthy donor monocytes, and (4) decreased IL-6 production by monocytes from HIV-positive patients.",
    "replication_status": null,
    "keywords": [
        "Flavopereirine",
        "HIV",
        "AIDS",
        "Beta-carboline",
        "Antiviral",
        "Plant extract"
    ],
    "related_technologies": [
        "AZT (zidovudine)",
        "Standard antiretroviral therapy"
    ],
    "controversy_level": "high",
    "confidence_score": 0.7,
    "practicability_score": 0.6,
    "fringe_score": 0.8,
    "evidence_strength": 0.4,
    "risk_score": 0.3,
    "trl_estimate": 4,
    "source_urls": [
        "http://en.wikipedia.org/wiki/Mirko_Beljanski",
        "http://www.beljanski.com/engl/about/",
        "http://www.youtube.com/watch?v=V-Tlz8jALvQ"
    ],
    "organizations": [
        "Beljanski Foundation",
        "CIRIS"
    ],
    "applications": [
        "HIV/AIDS treatment",
        "Immune system support"
    ],
    "limitations": [
        "Limited peer-reviewed clinical data",
        "No large-scale randomized controlled trials reported",
        "Potential variability in plant extract composition"
    ],
    "open_questions": [
        "Long-term safety and toxicity profile",
        "Comparative efficacy versus approved antiretroviral drugs",
        "Optimal dosing regimen for humans"
    ],
    "red_flags": [
        "Claims of superiority to AZT without robust clinical evidence",
        "Patented formulation marketed without regulatory approval in many jurisdictions"
    ],
    "evidence_quotes": [
        "Flavopereirine taken alone may act as an effective active agent in the struggle against HIV viruses in mammals, including humans.",
        "The flavopereirine, or one of its salts or other acceptable pharmaceutical derivatives, is preferably administered in solid form containing approximately 250-500 mg of flavopereirine per dose.",
        "Figure 1 shows comparative counts of cells/ml as a function of the number of hours following infection, the addition of flavopereirine having been made 12 hours after infection.",
        "Figure 3 represents the effect of flavopereirine on the production of interleukin-6 by human monocytes from healthy donors."
    ]
}